Sam Farrington Iii Email & Phone Number

Jackson, Ms, Us

Seattle, Wa, Us

Responsible for the promotion, integration and back office training for ClonoSEQ assay for Measurable Residual Disease (MRD) to all community Hematology/Oncology practices in Mississippi & Louisiana.

Cambridge, Ma, Us

Oversees the launch and sales of Reblozyl (luspatercept), a 1st in class erythroid maturation agent (EMA) for anemia due to myelodysplastic syndromes. Provides guidance and works collaboratively with Hematologists, Oncologists, APP’s, NP’s, PA’s, PharmD’s, RN’s, and Office Managers in Academic, Veteran Affairs, Department of Defense, and Community Practices. Creates detailed account plans and monitors lifecycles of consulting engagements from initial scoping through contracting. Co-promotes with BMS and collaborates cross-functionally with their territory reps, clinical nurse educators, and field reimbursement managers. Notable Contributions: • Successfully launched the 1st in class erythroid maturation agent, Reblozyl/luspatercept SC injection for patients with MDS.• Led the district in % volume growth for 2021 at Acceleron.• Achieved a top 50% ranking in the first year of the launch and was ranked #8 out of 17 representatives at Acceleron. • Secured 70 new customer accounts and averaged 138% in IC payout for Q3 and Q4 in 2020.• Completed Acceleron’s inaugural sales leadership training program. • Presented NCCN guidelines for MDS to district.• Led the district in Reblozyl promotional activities at educational vendor afairs.

Morris Plains, New Jersey, Us

Successfully led the launch, sales, and marketing of Balversa- an oral FGFR inhibitor for metastatic urothelial carcinoma across Mississippi and Louisiana territories. Analyzed the local market, developed, executed and monitored performance and results to maximize the appropriate use of the product in the defined territory. Provided current and comprehensive clinical knowledge on the product which included information on a diagnostic test for FGFR2/FGFR3 genetic alterations. Worked collaboratively with medical professionals in order to determine the clinical benefits of the product.Notable Contributions: • Launched the 1st FDA approved oral FGFR inhibitor, Balversa/erdafitinib in mUC at Immunomedics.• Educated customers on the 1st FDA approved Cdx for FGFR genetic alterations.• Drove early adoption of NGS testing for FGFR 2/3 in major academic, VA, and community accounts.• Completed required training on Sacituzumab govitecan (Trodelvy).• Appointed to the compliance committee.

Los Angeles, Ca, Us

Spearheaded the launch, sales, and marketing of Nerlynx, a TKI inhibitor, for those in early stage HER2+ breast cancer for the extended adjuvant setting. Identified and built advocacy channels by working with and providing important information and support to oncologists, nurse practitioners, physician assistants, PharmD’s, nurses, and social workers. Developed detailed account plans and worked collaboratively with CNE, NAM’s, marketing, and in-office dispensing pharmacies. Notable Contributions: • Achieved a top 20% national ranking and was ranked #2 out of 8 representatives in the district.• Secured 25 individual Nerlynx RXers from 14 different accounts. • Received recognition for outstanding industry knowledge and was appointed to the East Director’s Council to provide feedback from the district.

Summit, New Jersey, Us

Oversaw the sale of Revlimid, Pomalyst, Vidaza, and Istodax which are cancer medicines that treat multiple myeloma, myelodysplastic syndromes, and lymphomas. Worked with community, academic, and VA hematology and oncology professionals in order to identify their patient needs and answer any questions regarding the medicines. Collaborated cross-functionally with CAM, NAM, a regional trainer, advocacy development, and patient support services. Notable Contributions: • Increased Revlimid sales by 500% between 2008 and 2016.• Recognized as a Diamond Club Award Winner for being among the top 15 sales representatives in the company. • Facilitated sales training classes for MDS salesforce expansion at the company’s home office.• Promoted to senior level.• HOC of the quarter.• Exceeded expectations on performance reviews.• Facilitated training workshops at District POA, Regional, and National sales meetings.

Basel, Baselstadt, Ch

Promoted Zometa, Femara, Sandostatin LAR, and Proleukin to Hematology and Oncology professionals in MS, TN, and Northern AL.

Acute Care hospital representative.